Patents by Inventor Hoffmann-La Roche Inc.

Hoffmann-La Roche Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140193397
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: July 10, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Hoffmann-La Roche Inc., Genentech. Inc.
  • Publication number: 20140079706
    Abstract: The present invention relates to the combination therapy of antibodies binding to human CSF-1R, characterized in binding to the (dimerization) domains D4 to D5 (SEQ ID No: 85) of the extracellular domain of human CSF-1R in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.
    Type: Application
    Filed: March 7, 2013
    Publication date: March 20, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20140073567
    Abstract: The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention.
    Type: Application
    Filed: January 17, 2013
    Publication date: March 13, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20140065707
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 6, 2013
    Publication date: March 6, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20140045742
    Abstract: The current invention comprises a fusion polypeptide comprising a serpin-finger polypeptide conjugated to a biologically active polypeptide optionally via a peptidic linker polypeptide. Another aspect is a protein complex of the serpin-finger fusion polypeptide and a serpin, wherein the fusion polypeptide is incorporated in the serpin into the middle of beta-sheet A as strand 4a. Also an aspect of the current invention is the in vitro preparation of the protein complex. The serpin-finger polypeptide targets and anchors the biologically active polypeptide with high affinity and functional spatial orientation.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 13, 2014
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20140038210
    Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.
    Type: Application
    Filed: February 15, 2013
    Publication date: February 6, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20140032127
    Abstract: The invention provides a method for the selection of cultivation component batches to be used in the cultivation of a mammalian cell expressing a protein of interest wherein at least two different components are employed in the cultivation.
    Type: Application
    Filed: May 3, 2013
    Publication date: January 30, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20140017232
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 16, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: HOFFMANN-LA ROCHE INC., GENENTECH. INC.
  • Publication number: 20140017231
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 16, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: HOFFMANN-LA ROCHE INC., GENENTECH. INC.
  • Publication number: 20140004104
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
    Type: Application
    Filed: January 31, 2013
    Publication date: January 2, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20130336959
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 19, 2013
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Hoffmann-La Roche Inc., Genentech. Inc.
  • Publication number: 20130336960
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 19, 2013
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Hoffmann-La Roche Inc., Genentech. Inc.
  • Publication number: 20130225588
    Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 29, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130217712
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 22, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130217713
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 22, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130217623
    Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 22, 2013
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20130217665
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 22, 2013
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20130210799
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R8 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: February 6, 2013
    Publication date: August 15, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130209478
    Abstract: This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 15, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130210843
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 15, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.